Yunxiao Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yunxiao Xu has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Guangsen Zhang
Department of Hematology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China
2 shared publications - Hongling Peng
Department of Hematology, The Second Xiangya Hospital, Central South University, Changsha, China
2 shared publications - Yewei Wang
Department of Hematology, The Second Xiangya Hospital, Central South University
2 shared publications - Ailian Sun
Department of Hematology/Institute of Molecular Hematology, The Second Xiangya Hospital, Central South University, No.139 Middle Renmin Road, Changsha, Hunan 410011, China
1 shared publication - Doudou Tang
Department of Respiratory Medicine, The Second Xiangya Hospital, Central South University, No.139 Middle Renmin Road, Changsha, Hunan 410011, China
1 shared publication - Guoyu Hu
Department of Hematology, Zhuzhou No.1 Hospital, Zhuzhou, 410011, Hunan, China
1 shared publication
Latest Publications
- 1 November 2020
- Published by Elsevier in Pathology - Research and Practice
- Vol. 216 (11) , 153212
LncRNA-NEAT1 promotes proliferation of T-ALL cells via miR-146b-5p/NOTCH1 signaling pathway
- 1 November 2020
- Published by Elsevier in Pathology - Research and Practice
- Vol. 216 (11) , 153212
LncRNA-NEAT1 promotes proliferation of T-ALL cells via miR-146b-5p/NOTCH1 signaling pathway
- Open Access
- 4 April 2019
- Published by Springer Nature in Cancer Cell International
- Vol. 19 (1) , 84
RNF8 is responsible for ATRA resistance in variant acute promyelocytic leukemia with GTF2I/RARA fusion, and inhibition of the ubiquitin–proteasome pathway contributes to the reversion of ATRA resistance
GTF2I-RARA is a newly identified RARA fusion gene in variant acute promyelocytic leukemia (APL) patients with t(7;17)(q11;q21). Clinical manifestation in the patient showed that it is a sort of ATRA-insensitive oncogene and is different from the classic PML-RARA in terms of therapeutic reaction. To reveal the functional characteristics and regulating mechanism of the GTF2I-RARA fusion gene, we established a GTF2I-RARA-transfected HL60 cell model and examined its sensitivity to ATRA by western blot, MTT assay, flow cytometry, and Wright-Giemsa staining. Coimmunoprecipitation and confocal microscopy were used to examine the binding of GTF2I-RARA and transcriptional corepressors. We also performed ChIP-seq to search for potential target genes. Immunoprecipitation, ubiquitination assay, western blot, luciferase assay, and real-time PCR were used to analyze the effects of RNF8 on RARA. Flow cytometry and Wright-Giemsa staining were used to study the effect of MG132 and ATRA on the GTF2I-RARA-transfected HL60 cell model. We confirmed resistance of GTF2I-RARA to ATRA. Compared with PML-RARA, GTF2I-RARA has a higher affinity to HDAC3 under ATRA treatment. Using the ChIP-sequencing approach, we identified 221 GTF2I-RARA binding sites in model cells and found that the RING finger protein 8 (RNF8) is a target gene of GTF2I-RARA. RNF8 participates in disease progression and therapy resistance in APL with the GTF2I-RARA transcript. Elevated RNF8 expression promotes the interaction between RARA and RNF8 and induces RARA Lys-48 linkage ubiquitylation and degradation, resulting in attenuated transcriptional activation of RARA. Our results suggest that RNF8 is a key GTF2I-RARA downstream event. Using the combination of MG132 and ATRA to treat GTF2I-RARA-HL60 cells, a synergistic effect leading to GTF2I-RARA-HL60 cell differentiation was confirmed. Taken together, the targeting of RNF8 may be an alternative choice for treatment in variant APL with GTF2I-RARA fusion.
- 4 April 2019
- Published by Springer Nature in Cancer Cell International
- Vol. 19 (1) , 84
Open AccessRNF8 is responsible for ATRA resistance in variant acute promyelocytic leukemia with GTF2I/RARA fusion, and inhibition of the ubiquitin–proteasome pathway contributes to the reversion of ATRA resistance
GTF2I-RARA is a newly identified RARA fusion gene in variant acute promyelocytic leukemia (APL) patients with t(7;17)(q11;q21). Clinical manifestation in the patient showed that it is a sort of ATRA-insensitive oncogene and is different from the classic PML-RARA in terms of therapeutic reaction. To reveal the functional characteristics and regulating mechanism of the GTF2I-RARA fusion gene, we established a GTF2I-RARA-transfected HL60 cell model and examined its sensitivity to ATRA by western blot, MTT assay, flow cytometry, and Wright-Giemsa staining. Coimmunoprecipitation and confocal microscopy were used to examine the binding of GTF2I-RARA and transcriptional corepressors. We also performed ChIP-seq to search for potential target genes. Immunoprecipitation, ubiquitination assay, western blot, luciferase assay, and real-time PCR were used to analyze the effects of RNF8 on RARA. Flow cytometry and Wright-Giemsa staining were used to study the effect of MG132 and ATRA on the GTF2I-RARA-transfected HL60 cell model. We confirmed resistance of GTF2I-RARA to ATRA. Compared with PML-RARA, GTF2I-RARA has a higher affinity to HDAC3 under ATRA treatment. Using the ChIP-sequencing approach, we identified 221 GTF2I-RARA binding sites in model cells and found that the RING finger protein 8 (RNF8) is a target gene of GTF2I-RARA. RNF8 participates in disease progression and therapy resistance in APL with the GTF2I-RARA transcript. Elevated RNF8 expression promotes the interaction between RARA and RNF8 and induces RARA Lys-48 linkage ubiquitylation and degradation, resulting in attenuated transcriptional activation of RARA. Our results suggest that RNF8 is a key GTF2I-RARA downstream event. Using the combination of MG132 and ATRA to treat GTF2I-RARA-HL60 cells, a synergistic effect leading to GTF2I-RARA-HL60 cell differentiation was confirmed. Taken together, the targeting of RNF8 may be an alternative choice for treatment in variant APL with GTF2I-RARA fusion.
- 1 May 2018
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 499 (2) , 99-104
C/EBPβ contributes to transcriptional activation of long non-coding RNA NEAT1 during APL cell differentiation
- 1 May 2018
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 499 (2) , 99-104
C/EBPβ contributes to transcriptional activation of long non-coding RNA NEAT1 during APL cell differentiation
- 19 October 2013
- Published by Springer Nature in International Journal of Hematology
- Vol. 98 (5) , 558-562
Clinical significance of Treg cell frequency in acute myeloid leukemia
This study was designed to investigate the clinical significance of peripheral blood CD4+ CD25+ CD127 low-regulatory T (Treg) cells in acute myeloid leukemia (AML) patients. Treg cells in the peripheral blood of 80 AML patients and 35 age-matched healthy controls were counted by flow cytometry. Correlations between the frequency of circulating Treg cells and disease status, treatment outcome, or prognosis were evaluated. The percentages of Treg cells in patients at diagnosis and during refractory/relapse were significantly higher than that in healthy controls. There was no significant difference in the percentages of Treg cells between patients in remission and healthy controls. After six cycles of chemotherapy, the percentage of Treg cells in patients who achieved complete remission was significantly lower than that in patients at diagnosis, but there was no difference in Treg frequency between refractory/relapse patients and patients at diagnosis. Treg cells in the peripheral blood of AML patients may play a suppressive role in host antitumor immune response. The frequency of Treg cells in peripheral blood may thus be used as a biomarker for predicting sensitivity to chemotherapy and prognosis of AML patients. Additionally, Treg number in peripheral blood could be used to monitor disease status and evaluate disease progression.
- 19 October 2013
- Published by Springer Nature in International Journal of Hematology
- Vol. 98 (5) , 558-562
Clinical significance of Treg cell frequency in acute myeloid leukemia
This study was designed to investigate the clinical significance of peripheral blood CD4+ CD25+ CD127 low-regulatory T (Treg) cells in acute myeloid leukemia (AML) patients. Treg cells in the peripheral blood of 80 AML patients and 35 age-matched healthy controls were counted by flow cytometry. Correlations between the frequency of circulating Treg cells and disease status, treatment outcome, or prognosis were evaluated. The percentages of Treg cells in patients at diagnosis and during refractory/relapse were significantly higher than that in healthy controls. There was no significant difference in the percentages of Treg cells between patients in remission and healthy controls. After six cycles of chemotherapy, the percentage of Treg cells in patients who achieved complete remission was significantly lower than that in patients at diagnosis, but there was no difference in Treg frequency between refractory/relapse patients and patients at diagnosis. Treg cells in the peripheral blood of AML patients may play a suppressive role in host antitumor immune response. The frequency of Treg cells in peripheral blood may thus be used as a biomarker for predicting sensitivity to chemotherapy and prognosis of AML patients. Additionally, Treg number in peripheral blood could be used to monitor disease status and evaluate disease progression.